Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?

On Nov. 21, shares of CRISPR Therapeutics (NASDAQ: CRSP) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies. After all, it's been less than a year since regulators in the U.S. and E.U. approved its first therapy, Casgevy, to treat two blood-based disorders.Casgevy's initial launch hasn't been as exciting as investors and its partner, Vertex Pharmaceuticals (NASDAQ: VRTX), had hoped. Less than a year into the launch, though, it's still too early to turn our backs on this innovative drugmaker. After all, in addition to Casgevy, it has five other therapy candidates in clinical-stage testing.To see if adding some shares to your portfolio now makes sense, let's look at why the stock's been beaten down, and what could lift it back up.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool